ReviewMicroRNA (Shariqah, United Arab Emirates)2026
Revealing miRNAs' Janus-Faced Nature: Transforming Cold Tumours into Immunotherapy Hotspots and Overcoming Chemoresistance.
Review in MicroRNA (Shariqah, United Arab Emirates), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In cancer research, tumour complexity and treatment resistance have become more prevalent. Especially microRNA (miRNA) modulation has recently come into light as a promising strategy in cancer immunotherapy, particularly in converting "cold" tumours with limited immune cell infiltration into "hot" tumours responsive to immunotherapy. Tumour microenvironments are influenced by miRNAs, while specific miRNAs are targeted in cold tumours to enhance the immune response, potentially improving therapeutic efficacy. A miRNA profiling approach may enable earlier cancer detection and personalized treatments, emphasizing its importance for oncology in the future. This review sheds light on miRNA's role in cold and hot tumour microenvironments, that how they can modulate depending on the tumour niche. Furthermore, therapeutic resistance might develop over time and aid to decrease the efficacy of miRNA regulation. To address the hurdles of finding relevant miRNAs to target, researchers may use high-throughput sequencing methods to characterise miRNA expression across tumour subtypes. They may also use bioinformatics tools and databases to analyse massive amounts of miRNA-related data and find prospective candidate miRNAs.
Indexed as
Identifiers
39886790What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.